293 related articles for article (PubMed ID: 24853339)
1. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
[TBL] [Abstract][Full Text] [Related]
2. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
3. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
4. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.
Koch C; Engele J
Mol Pharmacol; 2020 Nov; 98(5):577-585. PubMed ID: 32883765
[TBL] [Abstract][Full Text] [Related]
5. ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin.
Saaber F; Schütz D; Miess E; Abe P; Desikan S; Ashok Kumar P; Balk S; Huang K; Beaulieu JM; Schulz S; Stumm R
Cell Rep; 2019 Feb; 26(6):1473-1488.e9. PubMed ID: 30726732
[TBL] [Abstract][Full Text] [Related]
6. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
7. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
8. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
[TBL] [Abstract][Full Text] [Related]
9. Ligand-specific conformational transitions and intracellular transport are required for atypical chemokine receptor 3-mediated chemokine scavenging.
Montpas N; St-Onge G; Nama N; Rhainds D; Benredjem B; Girard M; Hickson G; Pons V; Heveker N
J Biol Chem; 2018 Jan; 293(3):893-905. PubMed ID: 29180449
[TBL] [Abstract][Full Text] [Related]
10. CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons.
Abe P; Mueller W; Schütz D; MacKay F; Thelen M; Zhang P; Stumm R
Development; 2014 May; 141(9):1857-63. PubMed ID: 24718993
[TBL] [Abstract][Full Text] [Related]
11. CXCR7 as a novel therapeutic target for advanced prostate cancer.
Gritsina G; Yu J
Oncogene; 2023 Mar; 42(11):785-792. PubMed ID: 36755058
[TBL] [Abstract][Full Text] [Related]
12. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.
Bayrak A; Mohr F; Kolb K; Szpakowska M; Shevchenko E; Dicenta V; Rohlfing AK; Kudolo M; Pantsar T; Günther M; Kaczor AA; Poso A; Chevigné A; Pillaiyar T; Gawaz M; Laufer SA
J Med Chem; 2022 Oct; 65(19):13365-13384. PubMed ID: 36150079
[TBL] [Abstract][Full Text] [Related]
14. The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets.
Puchert M; Engele J
Cell Tissue Res; 2014 Feb; 355(2):239-53. PubMed ID: 24292718
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12.
Del Molino Del Barrio I; Wilkins GC; Meeson A; Ali S; Kirby JA
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30441765
[TBL] [Abstract][Full Text] [Related]
16. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.
Odemis V; Lipfert J; Kraft R; Hajek P; Abraham G; Hattermann K; Mentlein R; Engele J
Glia; 2012 Mar; 60(3):372-81. PubMed ID: 22083878
[TBL] [Abstract][Full Text] [Related]
17. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
[TBL] [Abstract][Full Text] [Related]
18. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
19. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.
Décaillot FM; Kazmi MA; Lin Y; Ray-Saha S; Sakmar TP; Sachdev P
J Biol Chem; 2011 Sep; 286(37):32188-97. PubMed ID: 21730065
[TBL] [Abstract][Full Text] [Related]
20. Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.
Szpakowska M; Nevins AM; Meyrath M; Rhainds D; D'huys T; Guité-Vinet F; Dupuis N; Gauthier PA; Counson M; Kleist A; St-Onge G; Hanson J; Schols D; Volkman BF; Heveker N; Chevigné A
Br J Pharmacol; 2018 May; 175(9):1419-1438. PubMed ID: 29272550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
